ClinicalTrials.gg
CompletedNCT02244281Updated Sep 19, 2014

Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

A Phase 2 interventional study of tamsulosin hydrochloride and Placebo in Lower Urinary Tract Symptoms, sponsored by Boehringer Ingelheim. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-19.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms — 5 open to participants now, 5 under way, none of them phase 3. Tamsulosin · Lower Urinary Tract Symptoms.

Enrollment
15th of 22
74 · median 136
Started
2001
the only one that year
Phase 2
4 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
2 of 22
Boehringer Ingelheim

Among the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, this one is the 15th largest by enrollment, is the only one that started in 2001, is one of 4 in phase 2, and was the 8th registered.

Lower Urinary Tract Symptoms

417 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

Browse Lower Urinary Tract Symptoms studies →

Open to participants now

5 of the 22 studies testing tamsulosin in Lower Urinary Tract Symptoms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tamsulosin

Tamsulosin: first FDA approval 1997 (FLOMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Lower Urinary Tract Symptoms studies recruiting now, 39 (66%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing tamsulosin in Lower Urinary Tract Symptoms, or all of them as a file.
02

Study summary

  1. To study the symptomatic improvement in LUTS afforded by FLOMAX® capsules, 0.4 mg daily compared to placebo, in female patients with lower urinary tract symptoms (LUTS) with a significant component of voiding symptoms
  2. To study the improvement afforded by FLOMAX® capsules versus placebo, in this patient population, in quality of life
  3. To assess the safety and tolerability of FLOMAX® capsules, 0.4 mg compared to placebo, in women suffering from LUTS with a significant component of voiding symptoms
03

Conditions studied

  • Lower Urinary Tract Symptoms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women, 18 years of age or older, currently diagnosed with LUTS with a significant component of voiding symptoms
  • The Patient must be diagnosed with one of the following: hesitancy, intermittency, difficulty in bladder emptying, or straining to void
  • Patients must have had an AUA Symptom Score of 13 or higher
  • Obstruction component of AUA Symptom Score (Items 1, 3, 5, and 6) had to be 5 points or higher
  • Patients that are currently taking alpha-blockers or anticholinergics must discontinue the drugs at least 2 weeks prior to Visit 1
  • Patients should show compliance of greater than or equal to 80% with placebo usage
  • Patients should be surgically sterile, or 2 years , or practicing a medically acceptable method of
  • Patients must have a negative urine Beta Human Chorionic Gonadotropin (beta-HCG)
  • Patients must be able to provide written prior to participation in the study in accordance with regulatory requirements
  • Patients must be judged by the investigator to be reliable and should comply with all tests and examinations stipulated in the protocol
  • All patients should be able to understand and read English

Exclusion criteria

Exclusion Criteria:

  • Patients who presented with an active urinary tract infection or who had presented with two or more culture positive urinary tract infections within 6 months of the study
  • Patients with significant prolapse beyond the hymenal ring, per the investigator's judgment
  • Patients who had taken anticholinergic medications for the treatment of other urologic conditions and had not discontinued their use 2 weeks prior to study entry
  • Patients who had a history or active condition of renal or urethral calculi, urethral colic, mechanical outlet obstruction (i.e., bladder neck contracture or stricture, bladder tumor, or bladder calculi) 3 months prior to study entry
  • Patients with a history of bladder, vaginal or urethral surgery in the last 6 months
  • Patients who have a history of microscopic hematuria and not had a recent work-up including cystoscopy and upper urinary tract study (within 6 months of screening) or a diagnosis of a condition that may exclude the patient in the opinion of the investigator
  • Abnormal urinalysis as defined by the following mid-stream, clean-catch specimen results:

    • A bacterial colony count of greater than 100,000/ml.
    • More than 10 leukocytes per high power field with more than two granular casts per high power field.
    • More than 10 red blood cells (non-menstrual tainted urine sample) per high power field.
    • Proteinuria >+1 (equivalent to >30 mg/dL)
  • Patients presenting with any of the following: history of a neurogenic bladder due to any neurologic condition that might involve the lower urinary tract, active urinary stone disease, previous pelvic radiotherapy, perirectal inflammatory disorder or inflammatory bowel disease
  • Patients that had a history of sexually transmitted diseases of the genitourinary system such as syphilis, herpes, gonorrhea, chlamydia, mycoplasma, trichomonas (within 3 months of the study) or any other diagnosis that in the opinion of the investigator may have excluded the patient
  • Patients that are pregnant or breast-feeding
  • The Patient has significant pelvic pain that demands treatment with narcotics
  • Large fluctuations in LUTS symptoms over the last 6 months (i.e., symptoms appearing and disappearing with unusual rapidity)
  • Any baseline (Visit 1) laboratory serum test with the following values: : \<11.0 g/dL, Leukocytes: \<3,000 per mm3, Liver enzymes [serum glutamic oxaloacetic transaminase / (SGOT/AST), serum glutamic pyruvic transaminase / Alanine transaminase (SGPT/ALT) or alkaline phosphatase]: more than two times the at baseline (Visit 1). Serum creatinine more than two times the upper limit of normal at baseline (Visit 1)
  • Patients with a diagnosis of cancer, except basal cell carcinoma, within the past 5 years. (Note: Contact the Trial Clinical Monitor with any specific or special circumstances regarding the entry of a cancer patient.)
  • Participation in another drug study within 4 weeks of baseline (Visit 1)
  • conditions which may interfere with the patient's ability to participate in the study including, but not limited to, the following: neurologic, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, hematologic or respiratory disease and clinically relevant laboratory abnormalities not mentioned above (e.g., hematuria) based upon the clinical judgment of the investigator
  • Patients who have been receiving cimetidine, ranitidine and warfarin medications within 2 weeks of screening and who would potentially use such medication during the course of the trial
  • Patients with known to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
  • Patients with a history of myocardial infarction within 6 months of baseline (Visit 1)
  • Patients with uncontrolled hypertension (systolic >160 mmHg, diastolic >100 mmHg) and patients with severe hypotension (systolic \<90 mmHg) after 5 minutes of sitting
  • Patients who have been using the following drugs, within 2 weeks prior to screening (Visit 1), and who are unable to discontinue these drugs over the course of the study

    1. Alpha-adrenergic blocking agents
    2. Alpha-adrenergic medication
    3. Drugs with systemic anticholinergic activity including antihistamines. Antihistamines allowed are Allegra®, Claritin® and Zyrtec®
    4. Antispasmodics or muscle relaxants
    5. Parasympathomimetics, cholinomimetics, and/or similar drugs
  • Patients with poorly controlled diabetes mellitus based upon urine with 2+ (or greater) glucose on urinalysis, performed at screening (Visit 1).
  • Patients who suffer from neurological diseases affecting the bladder (i.e., multiple sclerosis, Parkinson's disease, stroke, and any bladder trauma that may have been an exclusion criterion in the opinion of the investigator)
  • Patients that have a neurological impairment or psychiatric disorder that prevents their comprehension of consent and their ability to comply with the protocol
  • Patients who had been diagnosed with interstitial cystitis according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) criteria
  • Patients that had a history of urethral syndrome whose treatment was other than dilation. Patients treated by dilation 3 months prior to study entry were allowed to participate in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
74 participants (actual)

Study arms

  • Experimental
    FLOMAX®

    Drug: tamsulosin hydrochloride

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of efficacy on a American Urological Association (AUA) Symptom Score Index

    Time frame: Up to day 56 after first study drug administration

Secondary outcomes

  1. Assessment of Quality of Life on a incontinence impact questionary and urogenital distress inventory

    Time frame: Up to day 56 after first study drug administration

  2. Assessment of urinary frequency and nocturia on a seventy-two hour voiding diary

    Time frame: Up to day 28 after first study drug administration

  3. Assessment of urinary obstruction

    by uroflowmetry

    Time frame: Up to day 56 after first study drug administration

  4. Assessment of Post-Void Residual volume

    by pelvic ultrasound

    Time frame: Up to day 56 after first study drug administration

  5. Assessment of lower urinary tract symptoms of obstruction

    (voiding, Items 1, 3, 5 and 6), irritation (storage, Items 2, 4 and 7) and nocturia (Item 7) by AUA Symptom Score Index sub scores

    Time frame: Up to day 56 after first study drug administration

  6. Number of patients with adverse events

    Time frame: Up to day 56 after first study drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2001 and a primary completion of Nov 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2014
First posted
Sep 19, 2014
Start
May 2001
Primary completionActual
Nov 2003
Last update
Sep 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02244281
Responsible party
Sponsor
First posted
Sep 19, 2014
Start date
May 2001
Primary completion
Nov 2003
Last update
Sep 19, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion